TW202334239A - 因子XI/XIa抗體之投藥方案 - Google Patents

因子XI/XIa抗體之投藥方案 Download PDF

Info

Publication number
TW202334239A
TW202334239A TW111144214A TW111144214A TW202334239A TW 202334239 A TW202334239 A TW 202334239A TW 111144214 A TW111144214 A TW 111144214A TW 111144214 A TW111144214 A TW 111144214A TW 202334239 A TW202334239 A TW 202334239A
Authority
TW
Taiwan
Prior art keywords
antibody
seq
chain variable
variable region
antigen
Prior art date
Application number
TW111144214A
Other languages
English (en)
Chinese (zh)
Inventor
黛柏拉 Ａ 芙德麗和
丹尼爾 Ｍ 布倫菲得
羅伊思頓 Ｊ 格拉司博
強納森 Ｅ 佛瑞曼
雅瑟 科德
Original Assignee
美商安瑟斯治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安瑟斯治療公司 filed Critical 美商安瑟斯治療公司
Publication of TW202334239A publication Critical patent/TW202334239A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW111144214A 2021-11-18 2022-11-18 因子XI/XIa抗體之投藥方案 TW202334239A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163281024P 2021-11-18 2021-11-18
US63/281,024 2021-11-18
US202163287633P 2021-12-09 2021-12-09
US63/287,633 2021-12-09
US202263355314P 2022-06-24 2022-06-24
US63/355,314 2022-06-24

Publications (1)

Publication Number Publication Date
TW202334239A true TW202334239A (zh) 2023-09-01

Family

ID=86397863

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111144214A TW202334239A (zh) 2021-11-18 2022-11-18 因子XI/XIa抗體之投藥方案

Country Status (8)

Country Link
US (1) US20240294669A1 (https=)
EP (1) EP4433088A4 (https=)
JP (1) JP2024540435A (https=)
KR (1) KR20240109269A (https=)
CA (1) CA3234626A1 (https=)
IL (1) IL311801A (https=)
TW (1) TW202334239A (https=)
WO (1) WO2023092062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
US20250388679A1 (en) * 2024-06-20 2025-12-25 argenx BV Subcutaneous fcrn antagonist formulations and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6321886B2 (ja) * 2014-05-15 2018-05-09 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 白血球減少症及び血小板減少症に対する治療方法
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Also Published As

Publication number Publication date
US20240294669A1 (en) 2024-09-05
WO2023092062A1 (en) 2023-05-25
KR20240109269A (ko) 2024-07-10
EP4433088A1 (en) 2024-09-25
CA3234626A1 (en) 2023-05-25
EP4433088A4 (en) 2026-01-14
JP2024540435A (ja) 2024-10-31
IL311801A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
TWI743039B (zh) 凝血因子ｘｉ抗體及使用方法
KR102576012B1 (ko) 고농도 항-c5 항체 제형
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
KR102553870B1 (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
JP2024116221A (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
TWI844571B (zh) 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JP7703513B2 (ja) 抗ガレクチン９抗体と化学療法剤の組合せがん治療
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
KR20180094028A (ko) 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
JP2015531397A (ja) 血管疾患及びその合併症の処置
BR112021001691A2 (pt) método de tratamento de câncer de ovário, câncer peritoneal ou câncer de trompa de falópio, e, kit
TW202214297A (zh) 用於治療疼痛之結合TGF-α及表皮調節素(EPIREGULIN)之抗體
JP2023502398A (ja) 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
JP2024544057A (ja) 血栓塞栓性疾患を予防及び／又は治療する方法
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
JP2025523506A (ja) 抗第ｘｉ因子／第ｘｉａ因子抗体との併用療法
AU2018361975A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
CN118302196A (zh) 因子XI/XIa抗体的给药方案
JP2022512721A (ja) 化膿性汗腺炎の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
WO2025124481A1 (zh) Tfpi抗体用于治疗血友病